Clinical Trial: NCT03264547
A Study to Compare Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab
Status:
COMPLETEDPhase:
Phase 3| Lead Sponsor: | Japan Breast Cancer Research Group |
| Information Provided By: | Japan Breast Cancer Research Group |
| Last Update Posted: | 2025-09-29 |
Study Overview
Brief Summary
To verify that combination therapy with trastuzumab + pertuzumab + eribulin brings similar PFS and better QOL compared to trastuzumab + pertuzumab + taxane in advanced/recurrent HER2-positive breast cancer patients who have no medical history of chemotherapy except ado-trastuzumab emtansine
Official Title
A Phase III Clinical Study to Compare the Combination Therapy of Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab (EMERALD)
Conditions
Breast Cancer
Intervention / Treatment
- Drug: Pertuzumab
- Drug: Trastuzumab
- Drug: Docetaxel
- Drug: Paclitaxel
- Drug: Eribulin
Other Study ID Numbers
- JBCRG-M06
Start Date (Actual)
2017-08-28
Primary Completion Date (Actual)
2024-12-31
Study Completion Date (Actual)
2024-12-31
Enrollment (Actual)
446
Study Type
Interventional
Phase
Phase 3
| Lead Sponsor: | Japan Breast Cancer Research Group |
| Information Provided By: | Japan Breast Cancer Research Group |
| Last Update Posted: | 2025-09-29 |
Study Overview
Brief Summary
To verify that combination therapy with trastuzumab + pertuzumab + eribulin brings similar PFS and better QOL compared to trastuzumab + pertuzumab + taxane in advanced/recurrent HER2-positive breast cancer patients who have no medical history of chemotherapy except ado-trastuzumab emtansine
Official Title
A Phase III Clinical Study to Compare the Combination Therapy of Eribulin Mesylate + Pertuzumab + Trastuzumab With Paclitaxel or Docetaxel + Pertuzumab + Trastuzumab (EMERALD)
Conditions
Breast Cancer
Intervention / Treatment
- Drug: Pertuzumab
- Drug: Trastuzumab
- Drug: Docetaxel
- Drug: Paclitaxel
- Drug: Eribulin
Other Study ID Numbers
- JBCRG-M06
Start Date (Actual)
2017-08-28
Primary Completion Date (Actual)
2024-12-31
Study Completion Date (Actual)
2024-12-31
Enrollment (Actual)
446
Study Type
Interventional
Phase
Phase 3